Ormeloxifene-Hyaluronic acid microfibers for breast cancer therapy

Ormeloxifene (ORM) is a drug widely used for the treatment of breast cancer. It is a lipophilic molecule that possesses highly favourable pharmacokinetic and pharmacodynamic properties. The anti-cancer activity of ORM can be improved by developing a formulation that offers targeted delivery. This can be achieved by encapsulation using hyaluronic acid (HA). Since HA-targeted receptors (CD44) are over expressed in breast cancer, lung carcinoma and cervical cancer cells; HA has been used as a drug carrier to improve drug delivery to suppress cancer growth. Therefore we have developed a novel ORM incorporated HA microfiber (HA-ORM) formulation using a newly modified method and characterized for morphology, particle size, encapsulation efficiency and in vitro drug release. The particle size of all the formulations was in micron range. The SEM images showed that the microfibers were bead free and had smooth surface. The in vitro drug release of the microfibers in pH 6.8 suggests the release of drug in a controlled manner. (c) 2020 Elsevier Ltd. All rights reserved. Selection and peer-review under responsibility of the scientific committee of the Second International Symposium "Functional Nanomaterials in Industrial Applications: Academy-Industry Meet".